PTH and osteoporosis: Abaloparatide (ABL), a synthetic PTH-related peptide analog that selectively binds to the RG conformation of PTH type 1 receptor, demonstrated increased BMD and reduced the risk of osteoporosis-related vertebral and nonvertebral fractures compared with placebo (PBO) or teriparatide among postmenopausal women with osteoporosis in the pivotal ACTIVE phase 3 trial [14] and its extension ACTIVExtend trial [15].